Mandate

Vinge advises Capillar in connection with Sweden’s first ever de-SPAC

Capillar and the minority shareholders have entered into an agreement to sell all shares in Spolargruppen Sverige AB, a Swedish leading player in pipe lining (so-called relining) and pipe flushing, to tbd30 AB (publ), a so called SPAC (Special Purpose Acquisition Company).

In connection with the proposed transaction, a process is initiated (so-called “de-SPAC” or company combination) which includes, among other things, that Nasdaq Stockholm AB examines the intended acquisition, application for listing and change of trading venue to Nasdaq First North Growth Market within the framework of Nasdaq Stockholm's regulations regarding SPACs.

As part of the continued financing, a number of institutional and other investors, including Lannebo Fonder and Carnegie Fonder, have undertaken to subscribe for 1,500,000 new class A shares in tbd30 in a directed new share issue at SEK 100 per share.

Vinges team primarily consists of Christina Kokko, Joacim Rydergård, Hannah Kajlinger and Philip Moré (M&A), Linnéa Sellström (Equity Capital Markets) as well as Matthias Schömer and Henrik Wastenson (Tax).

Related

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of MedMera Bank AB

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of all shares in MedMera Bank AB from Kooperativa Förbundet for a total consideration of SEK 1,960 million. The transaction positions Morrow Bank as a leading Nordic platform in consumer finance with combined gross loans of SEK 28.2 billion.
March 24, 2026

Vinge advises NEWS, a portfolio company of Litorina, in connection with the sale of Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG

Vinge advises Northern Environmental and Water Solutions AB (“NEWS”), a portfolio company of Litorina, in connection with the sale of the operating subsidiaries Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG (Vienna Stock Exchange: WIE). The transaction is expected to be completed in Q2 2026.
March 24, 2026

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026